The Motley Foolยท2025-08-13 22:27Core Insights - The article emphasizes that quality stocks, particularly dividend-paying ones, can be attractive investment opportunities when they are undervalued in the market [1][2]. Group 1: Merck - Merck's revenue is heavily reliant on its cancer drug Keytruda, which accounts for 50% of total revenue, and faces patent expirations in the U.S. by 2028 and in Europe by 2031, contributing to a 39% decline in stock price from last year's peak [3][6]. - Despite current challenges, Merck has a promising pipeline with up to 20 drugs that could collectively generate over $50 billion in annual sales by the mid-2030s [5][6]. - The stock is currently priced at less than 9 times expected earnings, with a dividend yield of 4%, indicating that challenges are already reflected in the stock price [7]. Group 2: Target - Target has struggled with a 3.8% decline in same-store sales and a 60% drop in stock price since late 2021, largely due to economic conditions and internal controversies [8][12]. - There are signs of potential economic recovery, with a slight increase in consumer confidence and GDP growth estimates, which could benefit Target's sales [9][12]. - The stock is priced at about 14 times expected earnings, with a forward-looking dividend yield of 4.3%, suggesting a reasonable risk-reward profile for investors [12]. Group 3: PepsiCo - PepsiCo has experienced a 26% decline in stock price since its 2023 high, but this downturn may have reached its limit [13]. - The company faces challenges from rising costs in its beverage and food segments, but it is adapting by introducing healthier product options and optimizing its supply chain [14][16]. - PepsiCo is well-positioned to benefit from a potential resurgence in consumer spending and the growing trend towards healthy snacks [16].